GammaDelta Therapeutics has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood. AML is the most common form of acute leukaemia in adults with an… Read More
Nano Biosols, an SME based at Liverpool Science Park, UK, has filed a patent for novel technology it has developed to enhance the sensitivity of lateral flow tests, enabling use across a much broader range of diseases. Lateral flow tests have been routinely used during the pandemic to… Read More
AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More
Oncodesign, Covalab, CheMatech and ABX-CRO have partnered to launch the DRIVE-MRT (Molecular RadioTherapy) solution. Designed to offer therapeutic development in nuclear medicine, this encompasses theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimisation, preclinical candidate drug generation and IND, to the design and management of clinical trials. DRIVE-MRT is based on… Read More
A team of scientists at the MRC University of Glasgow Centre for Virus Research has revealed key research into the natural human antiviral defences against SARS-CoV-2, the virus that causes Covid-19. In the study, the scientists reveal that some people have a version of a gene,… Read More
In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD). Challenges and Opportunities in Protein Degradation, took place on… Read More
Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes… Read More
Twist Bioscience has reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094) demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of Covid-19. The Coronavirus Immunotherapy… Read More
AstraZeneca will present data across its Covid-19 and respiratory syncytial virus (RSV) pipeline as three late-breaking oral presentations at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases. The presentations include AZD7442 long-acting antibody combination… Read More
Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, we review how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, disease modelling, and the… Read More
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants. The awards are intended to fuel vaccine… Read More
September 2021 has been Cancer Awareness Month for Blood, Childhood, Gynaecologic, Ovarian and Prostate Cancer, which affect millions of people around the world annually. Here is a round-up of eight of some of the innovative research and studies being done in order to tackle these various types of cancer. … Read More
Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic. “Artificial intelligence and machine learning continue to play… Read More
Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More
Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences. Azenta will bring together Brookes’ existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions. “We are excited to announce the creation of Azenta as… Read More
By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by… Read More
